Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab versus pembrolizumab + carboplatin + pemetrexed for PD-L1-high non-squamous NSCLC
jRCTs031200078Completed
- Sponsor
- National Hospital Organization
- Start
- Aug 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in Non-small cell lung cancer (NS-NSCLC) comparing Pembrolizumab monotherapy with Pembrolizumab + carboplatin + pemetrexed (2 arms). Primary endpoint: progression-free survival. Started Aug 2020; status: completed.
02
Drugs
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCTs031200078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200078.